Ways Of Maximizing Value Through Collaborations To Be Discussed By Catalent At ON Helix
SOMERSET, N.J. – June 27, 2019 — Catalent, the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming ON Helix conference to be held at the Cambridge Building, Babraham Research Campus, Cambridge, U.K. on July 9 – 10, 2019.
On Tuesday, July 9 at 2:45 p.m., Dr. Harris will present in a panel session alongside Marta Helena Lesko of Merck and Julie Little from CRUK, titled “Maximizing Value Through Collaborations”. They will begin the session by presenting several case studies showing how collaboration can facilitate the decision-making process, before moving to a panel discussion where they will debate the added value development experts can bring to projects, how to choose partners and when partners should come on board.
Dr. Harris has over 35 years’ experience in the pharmaceutical industry. He started his career in technical support roles with R.P. Scherer, Warner Lambert and Glaxo Wellcome before spending time in academia as a Research Fellow at University of Manchester. For the past 15 years, Dr. Harris has worked in the pharmaceutical contract development and manufacturing sector, holding senior technical roles with Quay Pharma, Capsugel, Penn Pharma and Juniper Pharma Services (now part of Catalent). He has overseen the development of numerous new drug candidates for clinical evaluation and maintains a keen interest in technologies for enhancing oral bioavailability for ‘challenging’ compounds, and the development of pediatric medicines.
To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR – email@example.com
+44 (0)7580 041073
Richard Kerns, NEPR
+44 (0)161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.